Chuan Sun, Managing Partner at the firm's Shanghai and Hong Kong offices, was quoted in a SCMP article that focuses on the recent wave of government-linked investment into China’s AI-driven drugmakers, set against Beijing’s broader push for technological self-reliance and ecosystem development.
According to Chuan, “China’s biotech fundraising cycle has started to recover over the past year, but remains below pre-pandemic levels after hitting a trough in 2022 and 2023, when many drug developers struggled to survive.”
He said a surge in out-licensing deals had helped support firms facing tighter funding conditions.
“China’s biotech industry now has a genuine voice on the global stage,” Chuan said. “If investors see strong technology and credible intellectual property, they are willing to channel capital.”
Read the full article.
Chuan SunManaging Partner, Shanghai and Hong Kong